Risk Factor: C
Class: Anti-infectives/ Antibiotics/anti-infectives
Fetal Risk Summary
No reports linking the use of novobiocin with congenital defects have been located. One study listed 21 patients exposed to the drug in the 1st trimester (1). No association with malformations was found. Because novobiocin may cause jaundice due to inhibition of glucuronyl transferase, its use near term is not recommended (2).
Breast Feeding Summary
Novobiocin is excreted into breast milk. Concentrations up to 7 g/ml have been reported with milk:plasma ratios of 0.10.25 (3,4). Although adverse effects have not been reported, three potential problems exist for the nursing infant: modification of bowel flora, direct effects on the infant, and interference with the interpretation of culture results if a fever workup is required.
- Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group, 1977:297, 301.
- Weistein L. Antibiotics. IV. Miscellaneous antimicrobial, antifungal, and antiviral agents. In Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 4th ed. New York, NY: Macmillan, 1970:1292.
- Knowles JA. Excretion of drugs in milka review. J Pediatr 1965;66:1068-82.
- Anderson PO. Drugs and breast feedinga review. Drug Intell Clin Pharm 1977;11:20823.